Key facts
- This page summarizes Craig Eagle's Form 3 filing for Telomir Pharmaceuticals, Inc. (TELO).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 08 Feb 2024, 17:46.
Craig Eagle - 08 Feb 2024 Form 3 Insider Report for Telomir Pharmaceuticals, Inc. (TELO)
- Reporting relationship
- Director
- Issuer ticker
- TELO
- Reported as of
- 08 Feb 2024
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 08 Feb 2024, 17:46:28 UTC
- Prior SEC filing
- 03 Jan 2024
- Next SEC filing
- 02 Apr 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Nathen Fuentes, Attorney-in-Fact for Craig Eagle
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Craig Eagle filed Form 3 for Telomir Pharmaceuticals, Inc. (TELO) on 08 Feb 2024.
Change
- Previous filing in this sequence was filed on 03 Jan 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TELO
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 487,805
- Date
- 08 Feb 2024
- Ownership
- Direct
* marks a reported price that did not pass the local price check.